GarudaTx is a biotechnology company focused on developing innovative therapies for rare diseases. The company leverages its proprietary gene therapy platform to create treatments that address unmet medical needs.

GarudaTx

Garuda Therapeutics seeks to create a world which eliminates the dependency on donor or patient cells for blood stem cell transplants. Our platform technology for generating off-the-shelf, self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible transgene-free blood stem cell therapies. Like bone marrow transplants, our technology could provide potentially curative therapies for more than 120 diseases. https://garudatx.com

Mass General Brigham Ventures

Monashee Investment Management

Aisling Capital

Ridgeback Capital

Sectoral Asset Management

Northpond Ventures

OrbiMed

Resilience

Cormorant Asset Management

Alexandria Venture Investments

Garuda Therapeutics

March 1 is #EmployeeAppreciationDay! Made up of science-driven individuals with a passion for serving patients, the #GarudaTx team is making our mission to build the future of blood #stemcell therapies a reality. 
 
Today and every day, we are incredibly grateful for the Garuda team and their dedication to delivering transformative medicines to patients.

Garuda is proud to recognize February 29 as #RareDiseaseDay – a day dedicated to raising awareness and inspiring action for the 300 million people living with a #RareDisease worldwide. 
 
At Garuda, we’re developing off-the-shelf, durable blood stem cell therapies with the potential to provide curative treatment options to millions of patients with rare diseases. 
 
Learn more about our approach: bit.ly/3NrS9t0

What does 2024 hold for #biopharma?
 
Garuda Therapeutics’ Co-founder, President & CEO Dhvanit Shah expects an increased appetite for off-the-shelf blood stem cell therapies due to their ability to bypass many challenges associated with current treatment options.
 
Check it out: bit.ly/49BZlfA

Congratulations to Rob Labriola, Executive Director of Regulatory Operations at Garuda, who has been selected to serve on the Drug Information Association (DIA) conference planning committee for DIA’s Regulatory Submissions, Information, and Document Management (RSIDM) Forum, taking place February 12-14, 2024 in North Bethesda, MD.
 
Rob will also lead the Forum track on Building and Sustaining Successful RSIDM Foundations. Register for this can’t miss event which will feature over 90 diverse speakers from regulatory, industry and academia: bit.ly/48PqknX

Garuda Therapeutics’ Co-founder, President & CEO Dhvanit Shah will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10 at 9:30 am PT.
 
We look forward to connecting in San Francisco.

COM:GARUDATX

GarudaTx

People Not Available